紫杉醇脂质体联合顺铂同步放疗对宫颈癌患者T淋巴细胞亚群、VEGF及SCCA水平的影响

Effects of paclitaxel liposome combined with cisplatin radiotherapy on T lymphocyte subsets VEGF and SCCA levels in patients with cervical cancer

目的 :探讨紫杉醇脂质体联合放疗对宫颈癌患者T淋巴细胞亚群、血管内皮生长因子(VEGF)及鳞状细胞癌抗原(SCCA)水平的影响。方法 :回顾性分析180例宫颈癌患者的临床资料,根据治疗方案不同将患者分为观察组(n=98)和对照组(n=82),观察组接受紫杉醇脂质体联合顺铂化疗同步放疗治疗,对照组接受顺铂化疗同步放疗治疗,两组患者根据疾病分期及临床治疗情况,接受4.5～6周治疗,期间均给予宫颈癌对症支持治疗。分别于治疗前及治疗结束后,检测两组患者血中CD3+、CD4+、CD8+、CD4+/CD8+、VEGF及SCCA水平。治疗结束6个月,分别进行疗效评定。结果 :治疗前:2组患者血中CD3+、CD4+、CD8+、CD4+/CD8+、VEGF及SCCA水平无明显差异。治疗后:观察组与本组治疗前比较,CD3+、CD4+及CD4+/CD8+水平均显著升高,CD8+、VEGF及SCCA水平显著降低;对照组与本组治疗前比较,血清VEGF及SCCA水平显著降低。且治疗后观察组CD3+、CD4+及CD4+/CD8+水平均明显高于对照组,CD8+、VEGF及SCCA水平明显低于对照组。观察组临床有效率(88.78%)明显高于对照组(76.83%)。结论 :紫杉醇脂质体联合放疗治疗宫颈癌,可以提升患者T淋巴细胞亚群水平,减少新血管生成,临床治疗效果较顺铂同步放射治疗显著。

Objective To explore the effect of paclitaxel liposome combined with radiotherapy on T lymphocyte subsets VEGF and SCCA levels in patients with cervical cancer. Methods A retrospective analysis was performed for 180 patients with cervical cancer. The patients were divided as observation group(n=98) and control group(n=82) according to the different treatment regimens. Patients in observation group were treated by paclitaxel liposome combined with cisplatin radiotherapy, while those in the control group were treated with cisplatin radiotherapy. The two groups were treated for 4.5~6 weeks based on the staging of the disease and the clinical treatment, and concurrent symptomatic supportive treatment were given to all patients. The serum levels of CD3+, CD4+, CD8+, CD4+/CD8+, VEGF and SCCA were detected in two groups before and after the treatment. The curative effect was evaluated respectively after 6 months after the end of the treatment. Results Before treatment, there was no significant difference in levels of serum CD3+, CD4+, CD8+, CD4+/CD8+, VEGF and SCCA in the 2 groups. After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than before treatment, and the levels of CD8+, VEGF and SCCA were significantly lower than before treatment. After treatment, the levels of serum VEGF and SCCA in the control group were significantly lower than that before treatment and the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the levels of CD8+, VEGF and SCCA were significantly lower than those in the control group. The clinical effective rate of the observation group(88.78%) was significantly higher than that of the control group(76.83%). Conclusion Paclitaxel liposome combined with radiotherapy in the treatment of cervical cancer can effectively improve the levels of the T lymphocyte subsets and reduce the generation of blood vessels. The effect of clinical treatment was more significant than the treatment of cisplatin radiotherapy.